Biotest Aktiengesellschaft(FRA) BIO3

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

Biotest Aktiengesellschaft Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$478.40

Net Income (TTM)

-$34.20

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

BIO3 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotest Aktiengesellschaft

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Industry

Biotechnology

Sector

Health Care

Employees

2,495

CEO

Peter Janssen, MBA

Website

www.biotest.de

BIO3 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Biotest Aktiengesellschaft Performance Analysis

Biotest Aktiengesellschaft annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 516,100,000	0.1%
2023	2023-12-31	USD 684,600,000	32.6%
2024	2024-12-31	USD 726,200,000	6.1%
2025	2025-12-31	USD 648,900,000	-10.6%

Biotest Aktiengesellschaft annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.80	-50.6%
2023	2023-12-31	USD 3.21	N/A
2024	2024-12-31	USD 0.67	-79.2%
2025	2025-12-31	USD -1.79	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2025YOY CHG

Revenue

$124.20

N/A

Gross Profit

$14.10

N/A

Gross Margin

11.35%

N/A

Market Cap

N/A

Market Cap/Employee

$0.46

N/A

Employees

2,495

N/A

Net Income

-$21.40

N/A

EBITDA

N/A

Quarterly Fundamentals

Name

Q1 2025YOY CHG

Total Cash

$710.50

N/A

Total Debt

$668.70

N/A

Accounts Receivable

$195.00

N/A

Inventory

$523.70

N/A

Long Term Debt

$639.80

N/A

Short Term Debt

$28.90

N/A

Return on Assets

-1.71%

N/A

Return on Invested Capital

39.99%

N/A

Free Cash Flow

N/A

Operating Cash Flow

-$58.10

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About BIO3

What is the current price of Biotest Aktiengesellschaft?

Biotest Aktiengesellschaft is trading at N/A per share.

What is the 52-week range for Biotest Aktiengesellschaft?

Over the past 52 weeks, Biotest Aktiengesellschaft has traded between N/A and N/A.

How much debt does Biotest Aktiengesellschaft have?

As of the most recent reporting period, Biotest Aktiengesellschaft reported total debt of $668.70M.

How much cash does Biotest Aktiengesellschaft have on hand?

Biotest Aktiengesellschaft reported $41.80M in cash and cash equivalents in its most recent financial results.

What is Biotest Aktiengesellschaft’s dividend yield?

Biotest Aktiengesellschaft does not currently have a dividend yield.

Biotest Aktiengesellschaft(FRA) BIO3

Biotest Aktiengesellschaft Financials at a Glance

BIO3 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Biotest Aktiengesellschaft

BIO3 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Biotest Aktiengesellschaft Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BIO3

What is the current price of Biotest Aktiengesellschaft?

What is the 52-week range for Biotest Aktiengesellschaft?

How much debt does Biotest Aktiengesellschaft have?

How much cash does Biotest Aktiengesellschaft have on hand?

What is Biotest Aktiengesellschaft’s dividend yield?

Premium Investing Services